CytomX Therapeutics has decided to press on with its Phase I clinical trial involving the investigational antibody-drug conjugate (ADC) CX-2051 despite a recent patient fatality during the study. The deceased patient, who began the trial with a single kidney, suffered a severe adverse event related to acute kidney injury, although CytomX attributed the cause of death to symptoms like vomiting, diarrhea, and nausea. The company highlighted the patient’s complex medical background in a statement dated August 13, 2025.
Part of the dose expansion group for CX-2051, the patient was slated to receive doses ranging from 7.2mg/kg to 10mg/kg every three weeks. After being notified of the death on July 11, 2025, CytomX promptly reported the incident to the US Food and Drug Administration (FDA) by July 18, adhering to regulatory obligations. Despite the setback, CytomX has received a green light to continue the trial, which has so far enrolled 73 patients diagnosed with colorectal cancer, with plans to share an update on Phase I data by the first quarter of 2026.
In a bid to reassure stakeholders, CytomX’s CEO and chair, Dr. Sean McCarthy, emphasized the company’s unwavering commitment to patient safety as they advance CX-2051’s development for colorectal cancer treatment. Nevertheless, the recent negative attention adds to the challenges faced by CytomX, including a securities class action lawsuit filed in 2020. The lawsuit accused the company of misleading investors about the effectiveness of its experimental cancer treatments, particularly CX-2009 and CX-072, and raised concerns about the safety profile of CX-2009.
Despite the earlier dismissal of the lawsuit by the US District Court for the Northern District of California, CytomX’s stock value plummeted by 36%, marking a downward trend that began in 2020. The company’s stock has steadily declined on the Nasdaq exchange, with a significant 74% drop in value since 2021. The recent Phase I developments led to a further 21% decrease in stock value, underscoring the challenges faced by the company amidst ongoing clinical trials.
While CytomX has forged strategic partnerships with prominent pharmaceutical players such as Amgen, Astellas, Bristol Myers Squibb (BMS), Moderna, and Regeneron, certain collaborations have been discontinued. Notably, both Amgen and BMS halted the development of CX-904 and other projects due to clinical observations and portfolio restructuring. Despite these setbacks, CytomX remains actively engaged in preclinical projects with its partners, showcasing resilience in its pursuit of innovative therapies.
Key Takeaways:
– CytomX Therapeutics is proceeding with its Phase I ADC trial despite recent challenges, including a patient death and legal issues.
– The company faces stock devaluation and negative publicity following setbacks in clinical trials and legal disputes.
– Strategic partnerships with major pharmaceutical companies have been crucial for CytomX, although some collaborations have been discontinued.
– CytomX’s commitment to patient safety and advancement in cancer treatment research remains central to its operations despite obstacles.
Read more on finance.yahoo.com